Zobrazeno 71 - 80
of 4 526
pro vyhledávání: ''
Publikováno v:
Clinical Infectious Diseases
There is a proliferation of clinical trials worldwide to find effective therapies for patients diagnosed with coronavirus disease 2019 (COVID-19). The endpoints that are currently used to evaluate the efficacy of therapeutic agents against COVID-19 a
Autor:
Garrett Keim, Preeti Jaggi, Edward M. Behrens, Alison C Tribble, Daniel E. Dulek, William R Otto, Michele M Loi, Randy Q. Cron, Hassan El Chebib, James A. Connelly, Caroline Diorio, April Yarbrough, Kelly Walkovich, Robert C. Fuhlbrigge, Jennifer E Girotto, Shanmuganathan Chandrakasan, Hamid Bassiri
Publikováno v:
Journal of the Pediatric Infectious Diseases Society
BackgroundImmune-mediated lung injury and systemic hyperinflammation are characteristic of severe and critical coronavirus disease 2019 (COVID-19) in adults. Although the majority of severe acute respiratory syndrome coronavirus 2 infections in pedia
Autor:
Jeffrey A. Linder
Publikováno v:
Clin Infect Dis
Publikováno v:
J Infect Dis
Patients with sepsis present across a spectrum of infection sites and severity of illnesses requiring complex decision making at the bedside as to when prompt antibiotics are indicated and which regimen is warranted. Many hemodynamically stable patie
Publikováno v:
The Journal of Infectious Diseases. 222:S110-S118
The Surviving Sepsis Campaign recommends immediate antibiotics for all patients with suspected sepsis and septic shock, ideally within 1 hour of recognition. Immediate antibiotic treatment is lifesaving for some patients, but a substantial fraction o
Publikováno v:
The Journal of Infectious Diseases. 222:S103-S109
Delayed administration of active anti-infective therapy is associated with increased rates of adverse events, mortality, and costs among sepsis patients. Inherent limitations of conventional culture identification methods and the lengthy turnaround t
Autor:
Derek R. MacFadden, Sandra A N Walker, Nick Daneman, Jerome A. Leis, Ruxandra Pinto, Marion Elligsen
Publikováno v:
Clinical Infectious Diseases. 73:e417-e425
Background Timely selection of adequate empiric antibiotics has become increasingly difficult due to rising resistance rates and the competing desire to apply antimicrobial stewardship (AMS) principles. Individualized clinical prediction models offer
Autor:
Josh Morrison, David Manheim, Nicholas Joseph, T. Greg McKelvey, Derek Foster, Alexander J Norman, Conor F Barnes, Steven Jiang, Megan Kinniment, Thomas C. Darton, Christopher W Bakerlee, Sophie M Rose, Linh Chi Nguyen, Michael R. McLaren
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases
Clinical Infectious Diseases
Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss 3 potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and
Autor:
Jennifer Le, Manjunath P. Pai, Catherine Liu, Michael J. Rybak, Thomas P. Lodise, Benjamin M. Lomaestro, Donald P. Levine, Annie Wong-Beringer, John S. Bradley, Holly D. Maples, Keith A. Rodvold, John C. Rotschafer, Bruce A. Mueller
Publikováno v:
J Pediatric Infect Dis Soc
Background Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area-under-the-curve to minimum inh
Autor:
Sten H. Vermund, Virginia E. Pitzer
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases
Clinical Infectious Diseases
Asymptomatic infection occurs for numerous respiratory viral diseases, including influenza and coronavirus disease 2019 (COVID-19). We seek to clarify confusion in 3 areas: age-specific risks of transmission and/or disease; various definitions for th